anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A photoprotective composition can be utilized for a variety of cosmetic compositions. A photoprotective composition comprises one or more photoactive agents, and a synergistic combination of polymers. The photoprotective composition can provide a substantially a complete film. The photoprotective composition may comprise an alkyl dimethicone, a polymer with ester linkages, and a phenyl silicone or stearate. The photoprotective composition can further comprise abietic acid and ester derivatives. The photoprotective composition can be a liquid such that it is easily and consistently dispensed from a bottle, pump or spray.
Exposure to indoor air pollutants (IAP) has increased recently, with people spending more time indoors (i.e. homes, offices, schools and transportation). Increased exposures of IAP on a healthy population are poorly understood, and those with allergic respiratory conditions even less so. The objective of this study, therefore, was to implement a well-characterised in vitro model of the human alveolar epithelial barrier (A549 + PMA differentiated THP-1 incubated with and without IL-13, IL-5 and IL-4) to determine the effects of a standardised indoor particulate (NIST 2583) on both a healthy lung model and one modelling a type-II (stimulated with IL-13, IL-5 and IL-4) inflammatory response (such as asthma).Using concentrations from the literature, and an environmentally appropriate exposure we investigated 232, 464 and 608ng/cm2 of NIST 2583 respectively. Membrane integrity (blue dextran), viability (trypan blue), genotoxicity (micronucleus (Mn) assay) and (pro-)/(anti-)inflammatory effects (IL-6, IL-8, IL-33, IL-10) were then assessed 24 h post exposure to both models. Models were exposed using a physiologically relevant aerosolisation method (VitroCell Cloud 12 exposure system).No changes in Mn frequency or membrane integrity in either model were noted when exposed to any of the tested concentrations of NIST 2583. A significant decrease (p < 0.05) in cell viability at the highest concentration was observed in the healthy model. Whilst cell viability in the "inflamed" model was decreased at the lower concentrations (significantly (p < 0.05) after 464ng/cm2). A significant reduction (p < 0.05) in IL-10 and a significant increase in IL-33 was seen after 24 h exposure to NIST 2583 (464, 608ng/cm2) in the "inflamed" model.Collectively, the results indicate the potential for IAP to cause the onset of a type II response as well as exacerbating pre-existing allergic conditions. Furthermore, the data imposes the importance of considering unhealthy individuals when investigating the potential health effects of IAP. It also highlights that even in a healthy population these particles have the potential to induce this type II response and initiate an immune response following exposure to IAP.
PURPOSE:To provide the titled remedy containing, as an active component, the extract liquid of cultured micelia of basidiomycetes such as Cortinellus shiitake cultured in a solid medium composed mainly of bagasse. CONSTITUTION:Fungus belonging to Basidiomycetes (e.g. Cortinellus shiitake, Pleurotus ostreatus, Flammulina velutipes, Pholiota nameko, Lyophyllum aggregatum, etc.) is inoculated in a solid medium containing 90% of crushed bagasse, 5% of rice sugar, and 5% of nutrient sources such as rice bran, and cultured at 18-20 deg.C and 60% RH. When the fruit bodies begin to grow from the surface of the medium, the medium is taken out of the culture tank, and crushed. The temperature of the crushed medium (cultured mycelia) is changed between 40 and 60 deg.C according to the pH to promote the enzymation of the medium under the condition matched with the enzyme in the medium. Finally, the medium is mixed at 60 deg.C, and the resultant suspension is filtered under pressure. The microorganisms are removed from the filtrate by filtration, and the resultant extract liquid is freeze-dried and pulverized to obtain the objective remedy for asthma.
Visual development disorders including amblyopia , strabismus ,refractive error are an important public health problem among children, and the visual impairment caused by visual development disorders is lifelong and can be profound. Timely discovering and treatment of visual development disorders are significant for the recovering of visual function in children. The national basic public health services of China offer the basic visual acuity screening every year for free. In this study, the investigators try to explore the cost-effective and compliance of the national basic public health services based tertiary care model for the management of visual development disorders among preschool children. This Tertiary care based on disease management model among preschool children was conducted at Yudu county, Jiangxi province, in China. Preschool vision screening relied on the national basic public health services of China (refractive errors examined by the Retinomax autorefractor). Children who failed the screening were randomized into two groups, the intervention group: their parents will be informed and transferred to an ophthalmologist and optometrist at Ophthalmic Referral Center, receiving basic eye examination and therapy (visual corrected by glasses and periodic review); The control group: their parents will be informed and suggest them to take their children to the hospital for further examination by themselves.
Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and can be used for surgical management of nodular and multinodular nontoxic goiter. For this purpose, at the first stage a thyroid gland is punctured with a puncture needle G19. The needle is moved to the centre of the goiter from the mid-line of an anterior surface of neck with ultrasonic guidance. Then 0.35% radachlorine 1 ml per 1 cm3 is injected. Then the needle is removed. At the second stage, 5-10 minutes later needle puncture is performed again, and a light guide is introduced through needle opening. It is followed by laser exposure at wave length 0.662 mcm, power 100 to 900 mWt for 11-20 minutes. If observing the presence of more than one palpable abnormality in the same lobe at the first and second stages, the needle introduced earlier is alternately moved in the centre of the following goiter, and similarly all the procedures are repeated for required number of times. ^ EFFECT: method ensures evident and permanent clinical effect with no thyroid tissue destruction with minimum tissue injures, provides achieving gradual regress of pathological process in tissues and its replacements by normal thyroid epithelium with no destructive changes, reducing risk of specific postoperative complication in the form of bleeding. ^ 1 ex
BACKGROUNDS: The hybrid-type nasolabial fold is a special, complex type of nasolabial fold with various causes, making it difficult to obtain an ideal effect with a single treatment.
OBJECTIVES: This study aimed to investigate the effect and complications of a comprehensive therapy combining microliposuction, radiofrequency, and fat grafting on hybrid-type nasolabial folds.
RESULTS: Twenty-one patients aged 27 to 45 (mean: 34.71±5.41) years, who underwent the therapy for hybrid-type nasolabial folds were retrospectively analyzed. All patients were followed up for 12 months. Two independent observers conducted postoperative follow-ups at 1 week and 12 weeks. One week postoperatively, the hematoma, mass nodule, and skin scald ecchymosis scores were 1.24±0.43, 1.62±0.58, and 1.48±0.59, respectively. At 12 weeks, the scores of mass nodules and skin scald ecchymosis decreased (1.19±0.39 and 1.05±0.21, respectively) without obvious hematoma. The WSRS grade decreased from 4.33±0.47 to 2.19±0.39 (P<0.001), and the hybrid-type nasolabial folds significantly improved. The Face-Q scale score was 20.43±2.63 points (standard score: 85.12±10.95 points). 76.19% of the patients scored more than 80 points in the subjective Face-Q evaluation.
CONCLUSION: Microliposuction and radiofrequency combined with fat grafting effectively treats hybrid-type nasolabial folds, resulting in high patient satisfaction. Most complications can be prevented, and optimal outcomes can be obtained by comprehensive surgical methods and correct procedures, which is thus worthy of clinical promotion.
OBJECTIVES: To determine the efficacy and safety of nintedanib in patients with anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis-associated interstitial lung disease (anti-MDA5+ DM-ILD).
METHODS: The study was a retrospective cohort design that evaluated patients with anti-MDA5+ DM who either received or did not receive nintedanib. Clinical symptoms, laboratory tests, and survival were compared in the two groups using a propensity score-matched analysis. The primary endpoint was mortality, while adverse events were recorded descriptively.
RESULTS: After propensity score matching, 14 patients who received nintedanib (nintedanib+ group) and matched 56 patients who did not receive nintedanib (nintedanib- group) were enrolled. Compared with the nintedanib- group, the nintedanib+ group had a lower incidence of heliotrope and arthritis, higher lymphocyte counts, lower serum ferritin levels, and greater 12-month survival (all p<0.005). Although lung function, HRCT score, and lung VAS were not statistically different between the two groups, the longitudinal study showed significant improvement in HRCT scores (p=0.028) and pulmonary VAS (p=0.019) in the nintedanib+ group. Adverse events occurred in 28.6% of patients, with the most common adverse event with nintedanib being diarrhoea.
CONCLUSIONS: Nintedanib may be effective for improving clinical symptoms, laboratory parameters, lung lesions, and survival in anti-MDA5+ DM. Diarrhoea was the most common adverse event associated with nintedanib, although the drug was well tolerated by most patients.
We report a case of small cell carcinoma of the urethra with inguinal lymph node metastases. A 50- year-old female patient presented with gross hematuria. Cystoscopy and computed tomography (CT) revealed a tumor surrounding the urethra and an inguinal lymphadenopathy. Biopsy of the urethral tumor demonstrated small cell carcinoma. Four courses of chemotherapy with etoposide and cisplatin, followed by 66 Gy of irradiation achieved complete remission. Unfortunately, 14 months later, positroemission-CT scan revealed recurrence of inguinal lymph node metastases. Although seven courses of chemotherapy with nogitecan were carried out, a new metastatic bone tumor developed. Amrubicin was administered as a third-line treatment, but was canceled after one course because of side effects. The patient died at 39 months after diagnosis. Small cell carcinoma of urethra with metastases has extremely poor prognosis, as is demonstrated by this case.
Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W.
BACKGROUND: Postoperative pulmonary complications (PPCs) are among the most severe complications following total hip arthroplasty revision (THAR), imposing significant burdens on individuals and society. This study examined the prevalence and risk factors of PPCs following THAR using the NIS database, identifying specific pulmonary complications (SPCs) and their associated risks, including pneumonia, acute respiratory failure (ARF), and pulmonary embolism (PE).
METHODS: The National Inpatient Sample (NIS) database was used for this cross-sectional study. The analysis included patients undergoing THAR based on NIS from 2010 to 2019. Available data include demographic data, diagnostic and procedure codes, total charges, length of stay (LOS), hospital information, insurance information, and discharges.
RESULTS: From the NIS database, a total of 112,735 THAR patients in total were extracted. After THAR surgery, there was a 2.62% overall incidence of PPCs. Patients with PPCs after THAR demonstrated increased LOS, total charges, usage of Medicare, and in-hospital mortality. The following variables have been determined as potential risk factors for PPCs: advanced age, pulmonary circulation disorders, fluid and electrolyte disorders, weight loss, congestive heart failure, metastatic cancer, other neurological disorders (encephalopathy, cerebral edema, multiple sclerosis etc.), coagulopathy, paralysis, chronic pulmonary disease, renal failure, acute heart failure, deep vein thrombosis, acute myocardial infarction, peripheral vascular disease, stroke, continuous trauma ventilation, cardiac arrest, blood transfusion, dislocation of joint, and hemorrhage.
CONCLUSIONS: Our study revealed a 2.62% incidence of PPCs, with pneumonia, ARF, and PE accounting for 1.24%, 1.31%, and 0.41%, respectively. A multitude of risk factors for PPCs were identified, underscoring the importance of preoperative optimization to mitigate PPCs and enhance postoperative outcomes.
OBJECTIVE: The Baha SoundArc coupling system has been developed as a non-surgical coupling of a Baha sound processor to the skull allowing the transfer of vibrational energy to the cochlear partition via bone conduction pathways. Today, there are several alternatives to this non-surgical approach as the Baha headband/test band, or the Baha Softband, or adhesive patches. Each of these current options have benefits and liabilities. The aim of the study was to evaluate pediatric experience and performance when using two non-surgical options, the Baha SoundArc compared to the Baha Softband.
METHODS: Twenty-five children with unilateral mixed or conductive hearing loss aged 5-12 years of age evaluated the use of the Baha SoundArc compared to their existing Baha Softband in a one month take home trial. Participants had a minimum of 3 months experience using the control, Baha Softband. Participants were assessed at baseline and one month following fit of the Baha SoundArc. Measures included an experience and use patient reported outcome, speech perception testing in quiet using Phonetically Balanced Kindergarten (PBK) words, and sound field audiometry.
RESULTS: Mean aided soundfield thresholds across the frequency range were 27.6 dB HL for Softband and 26.0 dB HL for SoundArc, which were not significantly different (P = >.05). Mean word recognition score was 80.8% when aided with the Softband device and 85.1% with the SoundArc, which was also not significantly different (P = >.05). Most children favored the aesthetics and usability of the SoundArc over Softband, but comfort ratings were largely similar for both devices.
CONCLUSIONS: Bone conduction sound processors mounted on a SoundArc or a Softband resulted in comparable improvements in aided thresholds and speech understanding in children suffering from conductive or mixed hearing loss. Both wearing modalities can be considered equivalent in terms of audiological outcomes, although both patients and clinicians preferred the usability and aesthetics of the SoundArc. The SoundArc provides an alternative wearing option for patients that may otherwise be discouraged by the aesthetics and usability of the Softband device.
GOV IDENTIFIER: NCT03333577.
The intervention will be applied every week for 6 weeks. The level of depression, resourcefulness, spiritual resourcefulness, and spiritual health will be tested at the first week before the intervention (T0), the 3rd week (T1), the 6th week right after the interventions (T2), 1 month follow-up after the interventions (T3), and 2 months post-intervention.
Subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will start treatment with P1101. The study drug will be subcutaneously injected once every 2 weeks, with the target dose being 500 µg. Subjects will receive an initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg from the subsequent week until Week 52. If the dose needs to be adjusted due to safety or tolerability consideration, it is allowed to be adjusted to the previous dose, but the target dose is preferred to be maintained during the treatment period.
The clinical utility of a type 2 diabetes mellitus (T2DM) polygenic risk score (PRS) in the East Asian population remains underexplored. We aimed to examine the potential prognostic value of a T2DM PRS and assess its viability as a clinical instrument. We first established a T2DM PRS for 5490 Korean individuals using East Asian Biobank data (269,487 samples). Subsequently, we assessed the predictive capability of this T2DM PRS in a prospective longitudinal study with baseline data and data from seven additional follow-ups. Our analysis showed that the T2DM PRS could predict the transition of glucose tolerance stages from normal glucose tolerance to prediabetes and from prediabetes to T2DM. Moreover, T2DM patients in the top-decile PRS group were more likely to be treated with insulin (hazard ratio = 1.69, p value = 2.31E-02) than were those in the remaining PRS groups. T2DM PRS values were significantly high in the severe diabetes subgroup, characterized by insulin resistance and β -cell dysfunction (p value = 0.0012). The prediction models with the T2DM PRS had significantly greater Harrel's C-indices than did corresponding models without it. By utilizing prospective longitudinal study data and extensive clinical risk factor information, our analysis provides valuable insights into the multifaceted clinical utility of the T2DM PRS.
Patients hospitalized for hematopoietic cell transplantation (HCT) experience physical and psychological symptoms that lead to a deterioration in quality of life (QOL). Integrating specialty palliative care (PC) reduces physical and psychological symptom burden and improves QOL during HCT hospitalization. However, specialty PC remains unavailable and underused at many HCT centers. Primary PC - or training HCT clinicians to deliver PC domains as part of routine practice - is an alternative model of supportive care. We have developed Sentinel, a primary PC intervention for HCT clinicians and patients. We will train HCT clinicians to deliver PC to patients before and during HCT hospitalization. This study will assess Sentinel's feasibility and acceptability.
We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
NEW MATERIAL:A bioactive substance having an effect for promotion of production of acetylcholinesterase on megakaryocyte-based cells. USE:A preventive and therapeutic agent for diseases accompanied by functional disorders of megakaryocytes and platelet. PREPARATION:For example, human-derived cell strain KHM-5M is cultured in a culture medium at 37 deg.C for 3 days and the resultant cell-floating liquid is then centrifuged using a high-speed refrigerated centrifuge to collect a supernatant. The resultant supernatant is concentrated using an ultrafiltration membrane and the resultant concentrated liquid is dialyzed overnight at 4 deg.C using 50mM sodium acetate buffer solution (pH5.5). The obtained dialysis-treated sample is subjected to cation-exchange chromatography and the obtained active fraction is subjected to electrophoresis using an SDS-polyacrylamide gel. The obtained fraction of 19KD-31KD molecular weight is treated with hydrophobic chromatography, anion-exchange chromatography and reverse phase chromatography in order for purification, thus obtaining the objective bioactive substance.
PROBLEM TO BE SOLVED: To obtain a medicine containing a phosphate as an active ingredient, having an action to increase a leaking quantity of parathyroid hormone and for increasing the amount of the parathyroid hormone useful for the treatment of osteoporosis, etc. SOLUTION: This medicine contains (A1 ) a phosphate (e.g. its salt such as a sodium or potassium salt) as an active ingredient. Further, the medicine is prepared as an oral dosage from such as pills, capsules, liquid preparations, beverage solutions, etc., and administered daily by 2-10mg/kg body weight, especially daily 3-6mg, based on the weight of the phosphate (A1 ). More concretely, e.g. one tablet of this medicine (A) is packed with two calcium tablets (B) as an auxiliary agent in one package so that each one of (B) can be taken in the morning at noon, and one (A) is taken before going to bed.
An infant care station that includes multiple operational modules that communicate with each other to carry out the infant care station functions. The multiple modules form part of a micro-environmental platform that allows for communication and power connections between all of the operational components required within the infant care station. The multiple modules communicate with each other utilizing a universal interface bus that includes power connections, communication connections and control connections between the multiple modules. Sensor data obtained by various sensors is stored using a standard data format. A data repository is included in one of the modules and is used to store sensor data obtained from the infant patient, operational protocols and other information needed to operate the infant care station. The data repository provides a central location for both data producers and data subscribers that are part of the micro-environment platform.
Tumor hypoxia is the situation where tumor cells are or have been deprived of oxygen. Hypoxic tumor cells are usually more resistant to radiotherapy and chemotherapy and more likely to develop metastasis. In head and neck cancer, tumor hypoxia is known to be an important prognostic factor for long term survival. \[18F\]HX4 is being developed as a diagnostic radiopharmaceutical for PET imaging to find a marker for hypoxia that can be used in standard clinical practice. Current hypoxia tracers lack reliable image quality and kinetics. Because of the short half life and clearance, we expect that \[18F\]HX4 will have a higher tumor to background ratio than current nitro-imidazole hypoxia markers such as \[18F\]-misonidazole. The clinical use of a reliable, non-invasive and easy to use hypoxia imaging agent could allow selection of patients most likely to benefit from hypoxia modifying therapies.

Included are eligible patients with head and neck squamous cell carcinoma (T2, T3, T4, any N, M0) with tumor diameter ≥ 2,5 cm of the oral cavity, oropharynx, hypopharynx or larynx, planned to be treated with curative primary radiation treatment (+/- concurrent chemotherapy). Before treatment a standard planning \[18F\]FDG PET-CT will be performed, a blood sample is drawn and baseline \[18F\]HX4 PET scans will be performed. 18F-HX4 scans will be repeated after radiotherapy treatment with 20 +/- 4 Gy (approximately two weeks). Three months after the end of treatment a \[18F\]FDG PET scan will be performed.